Paul Thurk is a Managing Director with ARCH Venture Partners.
Mr. Thurk joined ARCH in 2000 as a Kauffman Fellow. In 2011, he established ARCH’s European office in Dublin, Ireland to focus on European-sourced technology and investment opportunities.
Mr. Thurk was co-founder and initial CEO of both Innovalight (acquired by DuPont) and CoolEdge Lighting. He has participated in the development of ARCH portfolio companies Kotura (acq by Mellanox), Nitronex (acq by MACOM), Cambrios, Semprius, Movidius (acq by Intel), Sana Biotechology, Luna DNA, Tune Therapeutics, BioPalette Japan, and others. He co-founded Carrick Therapeutics and Genomics Medicine Ireland. He is co-founder and current CEO of Pretzel Therapeutics.
Mr. Thurk originally began at ARCH focusing on semiconductors, advanced materials, electronics and optoelectronics and was a key part of ARCH’s efforts at Los Alamos and Sandia National Laboratories in conjunction with the U.S. Department of Energy. More recently, he has been focused on genomics, cell and gene therapies, and other novel therapeutics.
Prior to ARCH, Mr. Thurk was a Director of Operations for NABS, a New York City based supplier of electronics components, where he specialized in supply chain management programs and established operations in several countries, finishing-up as head of Asia Pacific.
Mr. Thurk holds a B.S. in Economics from the Wharton School of the University of Pennsylvania and an M.B.A. from the University of Texas at Austin.